AVEO licenses Peptech's Superhumanisation technology

Australian drugmaker Peptech and the USA's AVEO Pharmaceuticals have entered into a non-exclusive research and commercialization agreement in which the latter will access the former's Superhumanisation technology to humanize internally-derived drug candidates. The platform allows for modifying antibodies generated in animals so that they retain their essential therapeutic properties but appear humanized and will therefore not be rejected by the immune system of patients receiving them.

Under the terms of the agreement, AVEO will provide Peptech an upfront payment for access to intellectual property and know-how surrounding the Superhumanisation methodology.

AVEO will utilize the technology in-house and will be responsible for future clinical development and commercialization of any products made using it. Peptech will receive annual license fees and payments upon successful achievement of preclinical and clinical milestones, as well as royalties on sales of any products resulting from the collaboration. Further financial terms were not disclosed.